SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?


To: FTJoe who wrote (563)4/6/1998 10:06:00 PM
From: Cacaito  Read Replies (1) | Respond to of 1491
 
FT joe, maybe Raloxifene, from Pfizer and Ligand

Rexinoids, Targretin from Ligand, together with Tamoxifen for treatment this is from a rat study. Very few side effects.

It is also in the plans (preclinical)for prevention. Targretin and Panretin are a very neat technology.



To: FTJoe who wrote (563)4/7/1998 8:55:00 AM
From: Henry Niman  Read Replies (1) | Respond to of 1491
 
FTJoe, It was probably Raloxifene which is LLY's Evista. There are several reviews on SERMs linked to home.att.net
There is also an older Wall Street Journal review at:
home.att.net